Abstract:
Urinary tract infections (UTIs) associated with indwelling urinary catheterization (IUC) in premature newborns (PNBs) pose a significant challenge in neonatal intensive care units (NICUs) due to the vulnerability of this population to infections and the necessity of invasive procedures. While bacterial UTIs have historically been predominant, there is a rising incidence of fungal pathogens, particularly non-albicans Candida strains like Candida glabrata and Candida tropicalis, attributed to broad-spectrum antibiotic use. Diagnosis of fungal UTIs in a PNB relies on culturing Candida spp. from properly collected urine samples, particularly critical in very low birth weight (VLBW) PNBs because of the risk of invasive candidiasis and associated complications. We present a case of an extremely premature newborn (EPNB) successfully treated for a UTI caused by C. glabrata with micafungin. Our case exhibits micafungin as a potentially safe and effective alternative for treating C. glabrata UTIs in neonates.
摘要:
与早产儿(PNBs)留置导尿管(IUC)相关的尿路感染(UTI)在新生儿重症监护病房(NICU)中提出了重大挑战,因为该人群容易感染和侵入性程序的必要性。虽然细菌UTI历来占主导地位,真菌病原体的发病率不断上升,特别是非白色念珠菌菌株,如光滑念珠菌和热带念珠菌,归因于广谱抗生素的使用。PNB中真菌UTI的诊断依赖于培养念珠菌。从正确收集的尿液样本中,由于侵袭性念珠菌病和相关并发症的风险,在极低出生体重(VLBW)PNBs中尤其重要。我们介绍了一例极度早产的新生儿(EPNB),成功治疗了米卡芬净引起的UTI。我们的案例显示米卡芬净是治疗新生儿光滑衣原体的潜在安全有效的替代品。